T cell dysregulation in SLE

Klaus Tenbrock; Thomas Rauen

doi:10.1016/j.clim.2022.109031

T cell dysregulation in SLE

Clin Immunol. 2022 Jun:239:109031. doi: 10.1016/j.clim.2022.109031. Epub 2022 May 6.

Authors

Klaus Tenbrock¹, Thomas Rauen²

Affiliations

¹ Dept of Pediatrics, Pediatric Rheumatology, RWTH Aachen University, Aachen, Germany. Electronic address: ktenbrock@ukaachen.de.
² Dept of Medicine, Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany.

PMID: 35526790
DOI: 10.1016/j.clim.2022.109031

Abstract

T helper cells aid B cells with the production of antibodies and thus play a central role in disease development of systemic lupus erythematosus (SLE). Numerous T helper cell abnormalities have been described in SLE patients that contribute to disease pathophysiology and provide suitable targets for therapeutic intervention. In addition, T effector cell also play a less well-defined role in SLE. This review focusses on underlying molecular mechanisms of different T cell alterations in SLE.

Keywords: CD4+ T cells; CD8+ T cells; Foxp3; Lupus; T follicular helper cells; Tregs.

Publication types

Review

MeSH terms

B-Lymphocytes
Humans
Lupus Erythematosus, Systemic*
T-Lymphocytes, Helper-Inducer
T-Lymphocytes, Regulatory